Radioactive ray of hope for deadly eye cancer
NCT ID NCT05496686
Summary
This is the first study in people testing a new radioactive drug called 225Ac-MTI-201 for uveal melanoma, a rare eye cancer that has spread. The main goal is to find the highest dose that is safe for patients who have already tried at least one other treatment. Researchers will give a single dose and closely monitor patients for side effects and to see if the drug helps shrink tumors.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UVEAL MELANOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
H. Lee Moffitt Cancer Center and Research Institute
RECRUITINGTampa, Florida, 33612, United States
Contact
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Conditions
Explore the condition pages connected to this study.